Drug Profile
Research programme: metabolic disorders therapy - Advinus Therapeutics/Merck
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Advinus Therapeutics; Merck & Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in India
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-disorders in India
- 04 May 2009 Preclinical trials in Diabetes mellitus in India (unspecified route)